Cargando…
Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
In locally advanced (LA) breast cancer (BC), neoadjuvant treatments have led to major achievements, which hold particular relevance in HER2-positive and triple-negative BC. Conversely, their role in hormone receptor positive (HR+), hormone epidermal growth factor 2 negative (HER2-) BC is still under...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278946/ https://www.ncbi.nlm.nih.gov/pubmed/32429381 http://dx.doi.org/10.3390/ijms21103528 |
_version_ | 1783543448808194048 |
---|---|
author | Barchiesi, Giacomo Mazzotta, Marco Krasniqi, Eriseld Pizzuti, Laura Marinelli, Daniele Capomolla, Elisabetta Sergi, Domenico Amodio, Antonella Natoli, Clara Gamucci, Teresa Vizza, Enrico Marchetti, Paolo Botti, Claudio Sanguineti, Giuseppe Ciliberto, Gennaro Barba, Maddalena Vici, Patrizia |
author_facet | Barchiesi, Giacomo Mazzotta, Marco Krasniqi, Eriseld Pizzuti, Laura Marinelli, Daniele Capomolla, Elisabetta Sergi, Domenico Amodio, Antonella Natoli, Clara Gamucci, Teresa Vizza, Enrico Marchetti, Paolo Botti, Claudio Sanguineti, Giuseppe Ciliberto, Gennaro Barba, Maddalena Vici, Patrizia |
author_sort | Barchiesi, Giacomo |
collection | PubMed |
description | In locally advanced (LA) breast cancer (BC), neoadjuvant treatments have led to major achievements, which hold particular relevance in HER2-positive and triple-negative BC. Conversely, their role in hormone receptor positive (HR+), hormone epidermal growth factor 2 negative (HER2-) BC is still under debate, mainly due to the generally low rates of pathological complete response (pCR) and lower accuracy of pCR as predictors of long-term outcomes in this patient subset. While administration of neoadjuvant chemotherapy (NCT) in LA, HR+, HER2- BC patients is widely used in clinical practice, neoadjuvant endocrine therapy (NET) still retains an unfulfilled potential in the management of these subgroups, particularly in elderly and unfit patients. In addition, NET has gained a central role as a platform to test new drugs and predictive biomarkers in previously untreated patients. We herein present historical data regarding Tamoxifen and/or Aromatase Inhibitors and a debate on recent evidence regarding agents such as CDK4/6 and PI3K/mTOR inhibitors in the neoadjuvant setting. We also discuss key issues concerning the optimal treatment length, appropriate comparisons with NCT efficacy and use of NET in premenopausal patients. |
format | Online Article Text |
id | pubmed-7278946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72789462020-06-15 Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives Barchiesi, Giacomo Mazzotta, Marco Krasniqi, Eriseld Pizzuti, Laura Marinelli, Daniele Capomolla, Elisabetta Sergi, Domenico Amodio, Antonella Natoli, Clara Gamucci, Teresa Vizza, Enrico Marchetti, Paolo Botti, Claudio Sanguineti, Giuseppe Ciliberto, Gennaro Barba, Maddalena Vici, Patrizia Int J Mol Sci Review In locally advanced (LA) breast cancer (BC), neoadjuvant treatments have led to major achievements, which hold particular relevance in HER2-positive and triple-negative BC. Conversely, their role in hormone receptor positive (HR+), hormone epidermal growth factor 2 negative (HER2-) BC is still under debate, mainly due to the generally low rates of pathological complete response (pCR) and lower accuracy of pCR as predictors of long-term outcomes in this patient subset. While administration of neoadjuvant chemotherapy (NCT) in LA, HR+, HER2- BC patients is widely used in clinical practice, neoadjuvant endocrine therapy (NET) still retains an unfulfilled potential in the management of these subgroups, particularly in elderly and unfit patients. In addition, NET has gained a central role as a platform to test new drugs and predictive biomarkers in previously untreated patients. We herein present historical data regarding Tamoxifen and/or Aromatase Inhibitors and a debate on recent evidence regarding agents such as CDK4/6 and PI3K/mTOR inhibitors in the neoadjuvant setting. We also discuss key issues concerning the optimal treatment length, appropriate comparisons with NCT efficacy and use of NET in premenopausal patients. MDPI 2020-05-16 /pmc/articles/PMC7278946/ /pubmed/32429381 http://dx.doi.org/10.3390/ijms21103528 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Barchiesi, Giacomo Mazzotta, Marco Krasniqi, Eriseld Pizzuti, Laura Marinelli, Daniele Capomolla, Elisabetta Sergi, Domenico Amodio, Antonella Natoli, Clara Gamucci, Teresa Vizza, Enrico Marchetti, Paolo Botti, Claudio Sanguineti, Giuseppe Ciliberto, Gennaro Barba, Maddalena Vici, Patrizia Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives |
title | Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives |
title_full | Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives |
title_fullStr | Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives |
title_full_unstemmed | Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives |
title_short | Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives |
title_sort | neoadjuvant endocrine therapy in breast cancer: current knowledge and future perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278946/ https://www.ncbi.nlm.nih.gov/pubmed/32429381 http://dx.doi.org/10.3390/ijms21103528 |
work_keys_str_mv | AT barchiesigiacomo neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives AT mazzottamarco neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives AT krasniqieriseld neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives AT pizzutilaura neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives AT marinellidaniele neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives AT capomollaelisabetta neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives AT sergidomenico neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives AT amodioantonella neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives AT natoliclara neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives AT gamucciteresa neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives AT vizzaenrico neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives AT marchettipaolo neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives AT botticlaudio neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives AT sanguinetigiuseppe neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives AT cilibertogennaro neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives AT barbamaddalena neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives AT vicipatrizia neoadjuvantendocrinetherapyinbreastcancercurrentknowledgeandfutureperspectives |